Dr. Azad on Third-Line Treatment Options in CRC

Video

In Partnership With:

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Nilofer S​aba Azad, MD, associate professor of oncology, Johns Hopkins ​University School of Medicine, ​director, Developmental Therapeutics Clinical Trials Program, Johns Hopkins Sidney Kimmel Cancer Center, discusses third-line treatment options for patients with colorectal cancer (CRC).

Patients with KRAS wild-type CRC can receive EGFR inhibitors, Azad says.

Additionally, patients whose tumors harbor a BRAF mutation should be treated with a BRAF inhibitor in combination with an EGFR inhibitor, explains Azad.

For the general population of patients with CRC, treatment selection is between TAS-102 (trifluridine/tipiracil; Lonsurf) and regorafenib (Stivarga) in the third-line setting, concludes Azad.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD